What is the efficacy of drug-eluting stents (DESs) and bare-metal stents (BMSs) used in percutaneous coronary intervention (PCI) for the treatment of STEMI?

Updated: Nov 27, 2019
  • Author: George A Stouffer, III, MD; Chief Editor: Karlheinz Peter, MD, PhD  more...
  • Print

Stone et al studied the safety and efficacy of DESs and BMSs in 3006 patients with STEMI who underwent primary PCI. [19] Patients were assigned in a 3:1 ratio to receive paclitaxel-eluting stents or otherwise identical BMSs. The paclitaxel-eluting stents significantly reduced angiographic evidence of restenosis and recurrent ischemia necessitating repeat revascularization at 12-month follow-up. The rates of death and stent thrombosis were similar for the two groups.

The STEMI guidelines recommend 1 year of P2Y12 inhibitor therapy for patients who receive a BMS or a DES with clopidogrel, prasugrel, or ticagrelor.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!